drugset / Trial / NCT02982915
Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a phase I/II, randomized, blinded and placebo-controlled study to test the safety and efficacy of Lomecel-B for improving vaccine immune response.
Timeline
- Start
- 2016-11
- Primary completion
- 2021-09
- Completion
- 2022-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mesenchymal stem cell | Cell therapy | 2e+07 cells | Intravenous |
| Subject | Mesenchymal stem cell | Cell therapy | 1e+08 cells | Intravenous |
| Background | Fluzone High Dose Vaccine | Vaccine | — | Intramuscular |
Indications
No indication recorded.